Selective serotonin reuptake inhibitors combined with venlafaxine in depressed patients who had partial response to venlafaxine: Four cases

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 5, 2003, Pages 889-891

  Gonul, Ali Saffet ^a   Akdeniz, Fisun ^a   Donat, Ozlem ^a   Vahip, Simavi ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Combination treatment; Selective serotonin reuptake inhibitors; Treatment resistant depression; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VALPROIC ACID; VENLAFAXINE;

ADULT; AGORAPHOBIA; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONSTIPATION; DEPRESSION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR DEPRESSION; MALE; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PSYCHIATRIC DIAGNOSIS; SIDE EFFECT; XEROSTOMIA;

EID: 0042131869     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00120-9     Document Type: Article

References (16)

1. Beique J.C., de Montigny C., Blier P., Debonnel G. Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. Synapse. 32:1999;198-211.
2. Bhatara V.S., Magnus R.D., Paul K.L., Preskorn S.H. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann. Pharmacother. 32:1998;432-436.
3. Fava M., Davidson K.G. Definition and epidemiology of treatment-resistant depression. Psychiatr. Clin. North Am. 19:1996;179-200.
4. Fawcett J. Antidepressant. Partial response in chronic depression. Br. J. Psychiatry. 26:1994;S37-S41. (Suppl.).
5. Gomez J.M., Perramon C. Combined treatment with venlafaxine and tricyclic antidepressants in depressed patients who had partial response to clomipramine or imipramine: initial findings. J. Clin. Psychiatry. 61:2000;285-289.
6. Hamilton M.A. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 23:1960;56-62.
7. Hoencamp E., Haffmans J., Dijken W.A., Huijbrechts I.P. Lithium augmentation of venlafaxine: an open-label trial. J. Clin. Psychopharmacol. 20:2000;538-543.
8. Kennedy S.H., McCann S.M., Masellis M., McIntyre R.S., Raskin J., McKay G., Baker G.B. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J. Clin. Psychiatry. 63:2002;181-186.
9. McCance-Katz E., Price L.H., Charney D.S., Heninger G.R. Serotonergic function during lithium augmentation of refractory depression. Psychopharmacology (Berl). 108:1992;93-97.
10. Mitchell P.B., Schweitzer I., Burrows G., Johnson G., Polonowita A. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression. J. Clin. Psychopharmacol. 20:2000;483-487.
11. Nierenberg A., Feighner J., Rudolph R., Cole J.O., Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J. Clin. Psychopharmacol. 4:1994;419-423.
12. Rush A.J., Thase M.E. Strategies and tactics in the treatment of chronic depression. J. Clin. Psychiatry. 58(Suppl. 13):1997;S14-S22.
13. Saiz-Ruiz J., Ibanez A., Diaz-Marsa M., Arias F., Padin J., Martin-Carrasco M., Montes J.M., Ferrando L., Carrasco J.L., Martin-Ballesteros E., Jorda L., Chamorro L. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. Prog. Neuropsychopharmacol. Biol. Psychiatry. 26:2002;1129-1134.
14. Sanchez C., Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol. 19:1999;467-489.
15. Thase M.E., Feighner J.P., Lydiard R.B. Citalopram treatment of fluoxetine nonresponders. J. Clin. Psychiatry. 62:2001;683-687.
16. Zarate C.A., Kando J.C., Tohen M., Weiss M.K., Cole J.O. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J. Clin. Psychiatry. 57:1996;67-71.